Aardvark Therapeutics (AARD) Share-based Compensation (2024 - 2026)
Aardvark Therapeutics (AARD) posted Share-based Compensation of $25.9 million for Q1 2026, up 1538.2% sequentially from $1.6 million in Q4 2025, and up 11015.88% YoY from N/an in Q1 2025.
Aardvark Therapeutics (AARD) Share-based Compensation (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Share-based Compensation for 3 years, with the latest figure at $25.9 million in Q1 2026.
- Quarterly Share-based Compensation rose 11015.88% year-over-year to $25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.9 million (up 4195.19% YoY) and the FY2025 annual result came in at $18.4 million, up 4091.34% from the prior year.
- Share-based Compensation improved to $25.9 million in Q1 2026 per AARD's latest filing, from $1.6 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $25.9 million in Q1 2026 and troughed at $53000.0 in Q2 2024.
- A 3-year average of $3.4 million and a median of $233000.0 in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation surged 247.76% in 2025, then jumped 11015.88% in 2026.
- Over 3 years, Share-based Compensation stood at $173000.0 in 2024, then jumped by 813.87% to $1.6 million in 2025, then soared by 1538.2% to $25.9 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $25.9 million, $1.6 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | - |
| 10 | Aardvark Therapeutics | 144.40 Mn | 70.48 Mn | - | 1.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.95 Mn |
| Jun 30, 2026 | 1.95 Mn |
| Mar 31, 2026 | 25.90 Mn |
| Mar 31, 2026 | 25.90 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 634,000.00 |
| Jun 30, 2025 | 634,000.00 |
| Mar 31, 2025 | 233,000.00 |
| Mar 31, 2025 | 233,000.00 |
| Dec 31, 2024 | 173,000.00 |
| Dec 31, 2024 | 173,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 53,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Mar 31, 2024 | 67,000.00 |